Our Market Access Strategy unit recently held a workshop focused on Joint Clinical Assessment (JCA) learnings.
The session brought together perspectives from Quantify Research and our sister companies within the athagoras Group creating a valuable opportunity to learn from practical experience […]
A good week in evidence, access, and collaboration.
Last Monday, 22 June, we had the pleasure of hosting Giuseppe Pileggi, CEO of athagoras, for the athagoras Townhall in Stockholm.
It was a valuable opportunity […]
TLV has published new general guidelines and version 7.0 of its handbook for pharmaceutical reimbursement and pricing applications. TLV’s new general guidelines and application regulations apply from 1 October 2026. For market access teams, this is not a methodological reset. […]
The first Joint Clinical Assessment report under the EU HTA Regulation is now published. It covers Ojemada® / tovorafenib, for paediatric low-grade glioma.
Across the Nordics, the message from national HTA agencies is consistent:
Do not resubmit clinical evidence already available through […]
Our team in Finland has grown significantly this year, and for that, we owe a huge thank you to our excellent clients and the outstanding work delivered by our consultants.
Our Finnish Modelling, Access & Strategy team combines extensive experience from […]
We have now completed our journey across Denmark, Sweden, Finland and Norway.
Four countries.
Four distinct strengths.
One shared evidence philosophy.
Denmark – deeply integrated national registries and a strong epidemiological tradition
Sweden– clinically rich quality registries embedded in routine care
Finland – structured secondary-use frameworks […]
Norway closes our Nordic RWD series for a reason.
A universal healthcare system, personal identifiers, and decades of national coverage enable true longitudinal follow-up across care settings.
This is not just data availability.
It is […]
This is the third installment of the RWD sources from the Nordics. This week’s highlight is Finland’s real-world data ecosystem; which is built on something rare: continuity.
📆 Since the 1960s, nationwide health […]
Denmark offers one of the world’s most robust environments for real-world evidence generation. Key strengths include:
1️⃣ Fast access to comprehensive data
The average time to fully process applications at the Danish Health Data […]
Sweden’s RWD ecosystem is one of the most powerful globally — rich in coverage, high in trust, and fully linkable across registers via the personal identity number unique to every resident.
Thousands of […]